Operating on the cutting edge of data, science
and innovation
SDI Labs was founded by two molecular cytogeneticists from UCLA with the purpose to combine molecular biology and cytogenetics for chromosome analysis
Under the leadership of current CEO, Ozman Mohiuddin, and his information technology-oriented administration team, SDI Labs turns to a more progressive model. Driven by data, science and automation, SDI Labs pivots to molecular diagnostics concentrating in the areas of infectious disease, women’s health, autoimmune health, and mental health
SDI Labs quickly mobilizes to adapt to global pandemic needs, incorporating a four-step comprehensive COVID-19 testing solution: test, track, treat and isolate
SDI Labs brings together experts from around the world to address the growing need for rapid deployment of testing capabilities during the pandemic
SDI’s SARS-CoV-2 RT-PCR Lab Developed Test receives one of the first FDA approvals under Emergency Use Authorization (EUA)
SDI Labs installs first series of robotic arms and liquid handling work cells, increasing throughput, reducing employee risk and dramatically improving reporting turnaround time
SDI Labs incorporates artificial intelligence (AI) and machine learning (ML) models to predict outcomes and detect anomalies to ultimately improve patient-centered care, facilitating the national tracking and tracing effort, and helping people get back to work when safe to do so